Johnson & Johnson reports 22% net income margin for Q2 2026, trailing Eli Lilly’s 37% margin from Q1 2026 filings.
Johnson & Johnson posted a 22% net income margin for the quarter ended June 28, 2026, reflecting steady but slower profitability growth. The company recently agreed to acquire Firefly Bio, reinforcing its focus on innovative medicine and medical technology segments.
Eli Lilly, by comparison, reported a 37% net income margin for the quarter ended March 31, 2026, following its acquisition of Centessa Pharmaceuticals. Lilly’s higher margin underscores its rapid scaling in diabetes and oncology markets, contrasting with JNJ’s stable but lower growth trajectory.
Data from company filings as of July 24, 2026, highlights the divergence in profitability trends between the two pharmaceutical giants.